AI-Native Pharma: Turning Novartis, Lilly and Pfizer into Live Strategy Engines

Executive context: pharma is becoming AI-native

Biotech, healthcare and pharmaceuticals are not just experimenting with AI; the sector is rebuilding its strategic operating systems around data, telemetry and augmented intelligence. Novartis is scaling AI across R&D, clinical development and manufacturing to compress timelines and improve yields. Pfizer is structuring 177 years of proprietary data and federating AI capabilities across the enterprise. Eli Lilly is turning its obesity pipeline into a data-driven growth engine.

For CXOs, this is no longer an R&D story. It is a strategy architecture story: who builds an AI-native operating system first—and who is stuck with static plans.

From AI projects to AI-native strategy OS

Most pharma companies still treat AI as a set of disconnected projects. Novartis, Lilly and Pfizer are moving in a different direction: AI as a core layer of the strategy OS, not a feature.

Three common moves stand out:

1. Data as strategic alpha, not exhaust
   Pfizer explicitly frames its 177 years of clinical and scientific data as its unique "alpha"—the compound advantage that grows with every experiment and trial. When data is treated as alpha, strategy shifts from "where do we cut costs" to "which data assets deserve disproportionate capital allocation".

2. Federated, not centralized, AI
   Pfizer is deploying a federated AI model: central platforms, distributed accountability. The center provides infrastructure and governance; business units own how AI rewires their workflows. This is exactly the pattern enablegrowth advocates in The IA Leader: Why Strategy is Augmented, Not Automated: human strategists stay in charge, AI becomes a pervasive capability.

3. AI fluency as a strategic capability
   Novartis and Pfizer are investing in formal AI fluency programs, certifying large portions of their workforce. This is not training as an HR initiative; it is capability-building for live strategy. Without fluency, you cannot run real-time telemetry or interpret AI-led signals.

Research from Boston Consulting Group (BCG) shows that companies with broad digital and AI fluency are significantly more likely to report outperformance on growth and margin. When pharma pairs that fluency with unique data, the result is a new type of strategic leverage.

Why Strategy OS beats static transformation roadmaps

Traditional transformation programs in pharma rely on long, static roadmaps: five-year plans, multi-year ERP rollouts, periodic portfolio reviews. In an AI-native world, those roadmaps break. Three Strategy OS principles become non-negotiable.

1. Intelligence-Augmented (IA), not AI-automated

Novartis’ AI build-out is explicit: AI accelerates discovery and decision-making, but scientists remain central. Pfizer’s AI narrative is similar: AI is embedded into how teams work, not a replacement.

For strategy, this matters. An IA-first operating model:

• Keeps "locked human edits" on critical decisions (trial design, go/no-go, market entry).
• Treats institutional memory—previous launches, market reactions, regulator feedback—as a structured memory layer, not an inbox archive.
• Uses AI to surface patterns, not to unilaterally change strategy.

This is the same logic we unpack in Strategy Without Memory Is Just Noise: if AI models cannot read your strategic memory, they will amplify noise rather than advantage.

2. Real-time telemetry instead of annual reviews

The pharma sector is doubling down on AI to reduce trial cycles and manufacturing variability. That is telemetry in action. A Strategy OS uses that telemetry beyond operations:

• Live Market Pulse on physician behavior, payer decisions, and competitor trial readouts.
• Automated staleness alerts when a launch plan or indication strategy is based on outdated assumptions.
• Continuous sensing of regulatory, pricing and access changes.

This is where AI-native pharma intersects with enablegrowth’s philosophy in The Strategy Flywheel: Why Feedback Loops Outperform Forecasts: feedback loops beat static forecasts. In biopharma, feedback loops are now powered by telemetry from trials, manufacturing plants and market data.

3. Modular strategic frameworking

Eli Lilly’s obesity franchise illustrates the need for modular strategy. The pipeline spans multiple mechanisms, indications and geographies. Regulatory timelines, competitive entrants and access dynamics vary by market. A monolithic "global obesity strategy" cannot adapt quickly enough.

A Strategy OS for an AI-native pharma should:

• Break strategy into modules: indication, region, channel, pricing, data partnerships, real-world evidence.
• Attach live signals to each module: trial outcomes, payer decisions, competitor actions.
• Allow micro-updates: change one module (e.g., EU access strategy) without rewriting the entire plan.

This modularity is central to enablegrowth’s view in Why Your Strategy is a Monolith (And How to Escape It). In pharma, modularity is the difference between reacting to signals and pre-empting them.

Perspective-Pivot: Incumbent vs Disruptor in AI-native pharma

Novartis, Eli Lilly and Pfizer do not occupy the same strategic stance. The Perspective-Pivot Engine (PPE) of Strategy OS forces leaders to make this explicit.

Strategic stance comparison

• Incumbent: scale, breadth, regulatory relationships.
• Disruptor: narrative, speed, willingness to rewrite business models.
• Observer: lagging stance, reacting to others’ moves.

PPE is not branding. It defines which signals matter, which options exist, and how AI is deployed. For example:

• Novartis can use AI partnerships and platforms to reset the economics of complex therapies and trials.
• Lilly can leverage telemetry from obesity programs to dynamically adjust access strategies, co-pay support and regional pricing.
• Pfizer can convert its AI-native restructuring and savings into bold portfolio bets beyond the patent cliff.

Actionable directives: from insight to execution

Pharma has suffered for years from strategy-report inflation: immaculate decks, minimal execution. An AI-native Strategy OS must close the loop.

In practice, that means:

• Every strategic choice (e.g., shifting trial recruitment strategy) is linked to a SWOT justification and the telemetry signal that triggered it.
• Action is codified as context-aware briefs and tasks: who changes the trial protocol, which market access team revises payer negotiations, which manufacturing site tunes yield.
• Tasks are monitored for strategy drag—the latency between signal and action.

When strategy drag is high, ROI collapses. Leaders should quantify this using tools like enablegrowth’s Strategy Drag Calculator and then redesign workflows and incentives around drag reduction.

For teams designing this shift, the Ultimate Strategic Planning Guide offers a blueprint for moving from static annual plans to a live, telemetry-driven planning cycle.

What board-level pharma strategy should look like in 2027

By 2027, the gap between AI-native pharma and traditional players will be visible in three board metrics:

• Time-to-signal: How quickly can the organization detect meaningful changes (trial outcomes, access shifts, competitive moves)?
• Time-to-decision: How quickly can it update strategy modules once a signal is detected—without waiting for the next annual cycle?
• Time-to-execution: How quickly do accountable teams implement those directives in trials, launches and access programs?

Boards that treat AI as a technology line item will not see these metrics. Boards that treat AI, data and telemetry as layers of a Strategy OS will.

For Novartis, Eli Lilly and Pfizer, the next edge is not just better models. It is better strategic operating systems: IA-first, telemetry-native, modular and execution-biased.

Manifesto-style CTA: build your AI-native Strategy OS

Biopharma is quietly rewriting the rules of strategy. The companies that win the next decade will not be those with the most AI pilots; they will be those with AI-native strategic operating systems—where data is alpha, telemetry is constant, and human strategists are augmented by live intelligence.

If you are an executive in biotech, healthcare or pharma and your strategy still lives in static decks, you are operating with structural drag. It is time to turn your organization into a live strategy engine.

enablegrowth built Strategy OS precisely for this era: to give leaders IA-first tools, real-time telemetry, modular frameworks and execution-grade directives that match the speed of Novartis, Eli Lilly and Pfizer.

If you want your strategy to move at the speed of your science, it is time to step into the live strategy era.

Join the waitlist for Strategy OS →